
Akebia Therapeutics (AKBA) Stock Forecast & Price Target
Akebia Therapeutics (AKBA) Analyst Ratings
Bulls say
Akebia Therapeutics Inc. is experiencing strong initial sales of its Vafseo product, with revenue projections expected to grow from $136 million in FY25 to $374 million by FY28, highlighting a significant market opportunity. The company's strategic focus on securing contracts with dialysis organizations has driven early commercial traction, with net sales guidance for the first quarter of 2025 anticipated to be between $10 million and $11 million, which is considerably higher than initial consensus estimates. Additionally, the company has demonstrated operational efficiency, recording combined R&D and SG&A expenses below consensus, prompting upward revisions in future spending estimates which support a positive outlook for continued growth.
Bears say
Akebia Therapeutics Inc. reported a net loss of $22.8 million in the fourth quarter of 2024, indicating ongoing financial difficulties as reflected in a loss of $0.10 per share. The company faces significant risks including a potentially limited commercial opportunity for Vafseo due to market dynamics and competition, alongside additional regulatory hurdles and intellectual property challenges that could delay product launches. Furthermore, projected revenues from their key products, Auryxia and Vafseo, indicate potential declines, particularly with Auryxia expected to experience reduced sales following its impending genericization, compounding the company’s financial uncertainties.
This aggregate rating is based on analysts' research of Akebia Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Akebia Therapeutics (AKBA) Analyst Forecast & Price Prediction
Start investing in Akebia Therapeutics (AKBA)
Order type
Buy in
Order amount
Est. shares
0 shares